-
-
£165k boost for brain injury survivors in the Scottish Borders
-
Posted in Industry News
-
05th Jul 2021
-
A new support service for brain injury survivors in the Scottish Borders
-
-
William Wordsworth’s former Lake District home transformed into neurorehabilitation centre
-
Posted in Industry News
-
05th Jul 2021
-
New neurorehabilitation centre combines traditional clinical therapies with physical activity outdoors.
-
-
Study to investigate the efficacy of opicapone in early-stage Parkinson’s disease (PD)
-
Posted in Courses & Conferences,Industry News
-
21st Jun 2021
-
News from Bial at the ENS
-
-
Call for improved brain injury knowledge in social workers
-
Posted in Industry News
-
10th Jun 2021
-
UKABIF campaigns for social worker education in brain injury
-
-
FDA Grants Accelerated Approval for Alzheimer’s Drug aducanumab
-
Posted in Industry News
-
09th Jun 2021
-
News from Biogen
-
-
Indoor way-finder launched at Chelsea & Westminster Hospital NHS Foundation Trust
-
Posted in Industry News
-
08th Jun 2021
-
Industry news
-
-
EC approves PONVORY (ponesimod)
-
Posted in Industry News
-
24th May 2021
-
News from Janssen
-
-
Merck Announces New Data Supporting Continued Use of MAVENCLAD (Cladribine Tablets) During the COVID-19 Pandemic
-
Posted in Industry News
-
06th May 2021
-
Mavenclad news from Merck
-
-
Real-world data in Parkinson’s disease patients with motor fluctuations assesses the clinical utility of Ongentys® (opicapone)
-
Posted in Industry News,Sponsored Feature
-
29th Apr 2021
-
Heinz Reichmann
-
-
NICE recommends Novartis’ Kesimpta®▼ (ofatumumab) for patients living with relapsing remitting multiple sclerosis (RRMS)
-
Posted in Industry News
-
21st Apr 2021
-
Industry news from Novartis